Table 3.
The sensitivity, specificity, and accuracy of decreased vascular endothelial growth factor (VEGF) immunohistochemical (IHC) score peri-therapeutically vs responder for prediction of response of FOLFIRI combined with bevacizumab
| Responder (N) | Non-responder (No.) (N) | P value | Odds ratio (95% CI1) | |
|---|---|---|---|---|
| Decreased peri-therapeutic VEGF score | < 0.001 | 2.857 | ||
| Yes | 37 | 0 | (1.572-5.192) | |
| No | 7 | 13 | ||
| Total | 44 | 13 |
1
CI: Confidence interval.
Sensitivity: 84.1% (71.6-96.6%). Specificity: 100%. Positive predictive value: 100%. Negative predictive value: 65.0% (48.7-81.3%). Accuracy: 87.7% (76.5-99.0%).